Madeleine Biondolillo medication information.

Alice K. Jacobs, M medication information .D., Sharon-Lise T. Normand, Ph.D., Joseph M. Massaro, Ph.D., Donald E. Cutlip, M.D., Joseph P. Carrozza, Jr., M.D., Anthony D. Marks, M.D., Nancy Murphy, B.A., Iyah K. Romm, B.S., Madeleine Biondolillo, M.D., and Laura Mauri, M.D. For the MASS COMM Investigators: Nonemergency PCI at Hospitals with or without On-Site Cardiac Surgery Since coronary balloon angioplasty was introduced into clinical practice in 1977, marked advances in technology, technique, adjunctive pharmacotherapy, and operator experience have led to higher rates of procedural success and lower prices of complications.1,2 Emergency coronary-artery bypass grafting , that was initially required in 6 to 10 percent of procedures,1,3 has turned into a rare event, with an incidence of 0.1 to 0.4 percent in contemporary studies.4-6 Moreover, as data helping the use of primary PCI for sufferers with ST-segment elevation myocardial infarction possess emerged, the necessity for timely usage of the procedure has justified the growth of emergency PCI to hospitals that do not have the ability for on-site cardiac surgery.7-9 Although there are limited data10,11 to support the practice of non-emergency PCI at hospitals that don’t have the capability for on-site cardiac surgery, there is concern about the ratio of risk to benefit in this setting, as reflected in the class IIb recommendation in the 2011 PCI guidelines.12 The Cardiovascular Individual Outcomes Analysis Team Non-Major PCI trial, that was reported after publication of the 2011 PCI guidelines, straight compared the outcomes of PCI procedures between hospitals with on-site cardiac surgery and those without on-site cardiac surgery, in a prospective, randomized, controlled trial.13 PCI performed at hospitals without on-site cardiac surgery was noninferior to PCI performed at hospitals with on-site cardiac surgery with respect to mortality at 6 weeks and the rate of main adverse cardiac occasions at 9 months.